Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375511 | 0.86 | — | — | |
| SCHEMBL2718937 | 0.86 | KMT2A (0.41) | CES2CES1 | |
| SCHEMBL4813468 | 0.80 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL327566 | 0.78 | CES2 (0.44) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL29333109 | 0.78 | CES2 (0.55) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL28425729 | 0.78 | CES2 (0.55) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL599277 | 0.78 | CES2 (0.55) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL29333093 | 0.78 | CES2 (0.55) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL4439030 | 0.77 | CES2 (0.42) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL29056312 | 0.77 | CES2 (0.42) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | claimed |
| WO-2006057868-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | claimed |
| CN-1192021-C | 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands | PFIZER LTD (US) | 2005-03-09 | — | — | CN | claimed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | claimed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | claimed |
| CN-1331679-A | 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands | PFIZER LTD (US) | 2002-01-16 | — | — | CN | claimed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | claimed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | claimed |
| US-20120298007-A1 | PROCESS FOR PRODUCING CELLULOSE ESTER FILM, CELLULOSE ESTER FILM, POLARIZATION PLATE AND DISPLAY UNIT | KONICA MINOLTA OPTO, INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20090306361-A1 | PROCESS FOR PRODUCING CELLULOSE ESTER FILM, CELLULOSE ESTER FILM, POLARIZATION PLATE AND DISPLAY UNIT | KONICA MINOLTA OPTO, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1819693-A1 | ANTITHROMBOTIC DIAMIDES | ELI LILLY AND COMPANY (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060233973-A1 | Cellulose ester film, manufacturing method thereof, optical film, polarizing plate and liquid crystal display | KONICA MINOLTA OPTO, INC. | 2006-10-19 | — | — | US | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-0296878-B1 | MODIFIED POLYSILOXANE-COATED SANITARY RUBBER ARTICLE AND PROCESS FOR ITS PRODUCTION | DAIKYO GOMU SEIKO LTD. (JP) | 1993-09-01 | — | — | EP | disclosed |
| US-5114794-A | Coatings for medical equipment and drug containers for biological injections; adhesion; bonding strength | DAIKYO GOMU SEIKO LTD. (JP) | 1992-05-19 | — | — | US | disclosed |
| US-5110621-A | Radiation with electrons, lasers, or ultraviolet rays to bond | DAIKYO GOMU SEIKO LTD. (JP) | 1992-05-05 | — | — | US | disclosed |
| EP-0296878-A2 | Modified polysiloxane-coated sanitary rubber article and process for its production | DAIKYO GOMU SEIKO LTD. (JP) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | CES2 50/4885CES1 254/4885HDAC8 2239/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | CES2 50/4885CES1 254/4885HDAC8 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.